Related Experiment Videos
Aclarubicin in advanced thyroid cancer: a phase II study
H Samonigg1, D K Hossfeld, J Spehn
1Department of Internal Medicine, Karl-Franzens-University at Graz, Austria.
European Journal of Cancer & Clinical Oncology
|August 1, 1988
Summary
Aclarubicin shows effectiveness in treating metastatic thyroid cancer, achieving a 22% objective remission rate. This chemotherapy offers a viable treatment option with manageable side effects for patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic thyroid cancer has limited treatment options.
- Chemotherapy is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy and safety of aclarubicin in patients with metastatic thyroid cancer.
- To determine the objective remission rate and survival time.
Main Methods:
- Intravenous administration of aclarubicin at 25-30 mg/m2 daily for 4 days.
- Treatment cycles repeated every 3 weeks.
- Evaluation of patient response and side effects.
Main Results:
- Objective remission rate of 22% (1 complete, 4 partial remissions).
- Mean survival time of 57 weeks.
- Common side effects included nausea (75%) and mild myelosuppression (63%).
Conclusions:
- Aclarubicin monotherapy is effective for metastatic thyroid cancer.
- The drug demonstrates a favorable safety profile with minor side effects.